Clinical evaluation using Custom Control Software technology in coaxial phacoemulsification.
The aim of this study was to evaluate the clinical outcomes of the Custom Control Software technology in coaxial phacoemulsification. This prospective, randomized, double-masked clinical trial was conducted at the Eye Center, Affiliated Second Hospital, College of Medicine, Zhejiang University. The patients were grouped according to nuclear sclerosis and randomly assigned to undergo conventional phacoemulsification or phacoemulsification using Millennium Custom Control Software (CCS). All surgeries were performed by a single surgeon. The phaco time and average power of phacoemulsification were recorded and then calculated as absolute phaco time (APT). Visual acuity, pachymetry, endothelial cell density and anterior chamber flare count of both groups were noted at preoperatively day 1 and 3 months after surgery. The APT of the CCS group was statistically lower than Conventional group in grades II, III and IV (P < 0.05) nuclear sclerosis, but the two groups had no statistically significant differences in the grade I group. At day 1 post surgery, there were significant differences in the thickened pachymetry (P = 0.047) and anterior chamber flare counts (P = 0.008) between two groups. At 3 months post surgery, the endothelial cell loss ratio showed statistical difference (P = 0.032) between two groups. Using CCS technology in coaxial phacoemulsification can provide lower APT and better power efficiency. This new power modulation may make the surgery safer and more effective than Conventional phacoemulsification.